1. Academic Validation
  2. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors

Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors

  • J Biol Chem. 2003 Dec 26;278(52):52964-71. doi: 10.1074/jbc.M309039200.
Harry Towbin 1 Kenneth W Bair James A DeCaprio Michael J Eck Sunkyu Kim Frederick R Kinder Anthony Morollo Dieter R Mueller Patrick Schindler Hyun Kyu Song Jan van Oostrum Richard W Versace Hans Voshol Jeanette Wood Sonya Zabludoff Penny E Phillips
Affiliations

Affiliation

  • 1 Novartis Pharma AG, CH-4036 Basle, Switzerland.
Abstract

LAF389 is a synthetic analogue of bengamides, a class of Marine natural products that produce inhibitory effects on tumor growth in vitro and in vivo. A proteomics-based approach has been used to identify signaling pathways affected by bengamides. LAF389 treatment of cells resulted in altered mobility of a subset of proteins on two-dimensional gel electrophoresis. Detailed analysis of one of the proteins, 14-3-3gamma, showed that bengamide treatment resulted in retention of the amino-terminal methionine, suggesting that bengamides directly or indirectly inhibited methionine aminopeptidases (MetAps). Both known MetAps are inhibited by LAF389. Short interfering RNA suppression of MetAp2 also altered amino-terminal processing of 14-3-3gamma. A high resolution structure of human MetAp2 co-crystallized with a bengamide shows that the compound binds in a manner that mimics peptide substrates. Additionally, the structure reveals that three key hydroxyl groups on the inhibitor coordinate the di-cobalt center in the enzyme active site.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-118953
    MetAps Inhibitor